These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2427402)

  • 21. Tissue plasminogen activator concentrations in major abdominal surgery. Relationship to postoperative deep vein thrombosis.
    Mellbring G; Nilsson T; Bergsdorf N; Wallén P
    Thromb Res; 1984 Nov; 36(4):331-4. PubMed ID: 6543038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
    Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N
    Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Thromboembolic disease and anomalies of fibrinolysis].
    Juhan-Vague I; Aillaud MF; Valadier J; Alessi MC; Serradimigni A
    Ann Med Interne (Paris); 1986; 137(6):471-4. PubMed ID: 3101564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased plasminogen activator but normal prostacyclin activity in rat veins during development of experimental thrombosis.
    Mysliwiec M; Villa S; Kornblihtt L; de Gaetano G; Donati MB
    Thromb Res; 1980 Apr 1-15; 18(1-2):159-65. PubMed ID: 6996209
    [No Abstract]   [Full Text] [Related]  

  • 25. Influence of moderate and strenuous daily physical activity on fibrinolytic activity of blood: possibility of plasminogen activator stores depletion.
    Keber D; Stegnar M; Keber I; Accetto B
    Thromb Haemost; 1979 Jun; 41(4):745-55. PubMed ID: 483247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin).
    Du XH; Glas-Greenwalt P; Kant KS; Allen CM; Hayes S; Pollak VE
    Clin Nephrol; 1985 Oct; 24(4):186-91. PubMed ID: 3933871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The fibrinolytic system and its activators].
    Seifried E
    Z Gesamte Inn Med; 1993; 48(6-7):272-82. PubMed ID: 8333223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.
    Lang NN; Gudmundsdóttir IJ; Boon NA; Ludlam CA; Fox KA; Newby DE
    J Am Coll Cardiol; 2008 Jul; 52(1):33-9. PubMed ID: 18582632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients.
    Brommer EJ; Schicht I; Wijngaards G; Verheijen JH; Rijken DC
    Thromb Haemost; 1984 Dec; 52(3):311-4. PubMed ID: 6085194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrinolytic responses to acute physical activity in older hypertensive men.
    DeSouza CA; Dengel DR; Rogers MA; Cox K; Macko RF
    J Appl Physiol (1985); 1997 Jun; 82(6):1765-70. PubMed ID: 9173939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
    Gram J
    Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Decreased fibrinolytic activity in venous walls of patients with venous thromboses].
    Hach V; Heyland H; Walter-Fincke R; Scharrer I
    Vasa; 1985; 14(4):336-9. PubMed ID: 4072368
    [No Abstract]   [Full Text] [Related]  

  • 33. Proteins of the fibrinolytic system in human thrombi.
    Robbie LA; Bennett B; Croll AM; Brown PA; Booth NA
    Thromb Haemost; 1996 Jan; 75(1):127-33. PubMed ID: 8713791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
    van Giezen JJ; Boon GI; Jansen JW; Bouma BN
    Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-activator inhibitors of plasminogen].
    Juhan-Vague I; Alessi MC; Aillaud MF
    Ann Biol Clin (Paris); 1987; 45(2):202-6. PubMed ID: 3113299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of plasminogen activator in human plasma using the method of fibrin/celite column chromatography--with special reference to the determination of fibrin adsorbable tissue-plasminogen activator by ELISA].
    Ieko M
    Hokkaido Igaku Zasshi; 1985 Nov; 60(6):834-47. PubMed ID: 4085966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Disorders of the liberation of tissue-type plasminogen activator (t-PA) from the venous wall as a cause for recurrent thromboses].
    Hach-Wunderle V; Scharrer I
    Vasa Suppl; 1993; 39():5-10. PubMed ID: 8322122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrinolytic effects of peroneal nerve stimulation in patients with lower limb vascular disease.
    Barnes R; Madden LA; Chetter IC
    Blood Coagul Fibrinolysis; 2016 Apr; 27(3):275-80. PubMed ID: 26397885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.